Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  4Sc AG    VSC   DE000A14KL72

4SC AG (VSC)
Mes dernières consult.
Most popular
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
09/18/2017 09/19/2017 09/20/2017 09/21/2017 09/22/2017 Date
4.444(c) 4.351(c) 4.452(c) 5(c) 5.278(c) Last
33 359 15 069 22 337 178 545 156 154 Volume
-3.39% -2.09% +2.32% +12.31% +5.56% Change
More quotes
Financials (€)
Sales 2017 4,70 M
EBIT 2017 -11,3 M
Net income 2017 -10,6 M
Finance 2017 22,2 M
Yield 2017 -
Sales 2018 4,95 M
EBIT 2018 -9,96 M
Net income 2018 -9,26 M
Finance 2018 14,3 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 29,7x
EV / Sales2018 29,8x
Capitalization 162 M
More Financials
Company
4SC AG engages in the development of small molecule drugs that targets cancer through epigenetic mechanisms.It also involves in the preclinical and clinical development of its products.Its assets are resminostat, 4SC-202, and 4SC-208.The company was founded by Ulrich Dauer, Daniel Vitt, Stefan... 
More about the company
Surperformance© ratings of 4Sc AG
Trading Rating : Investor Rating :
More Ratings
Latest news on 4SC AG
09/13 4SC : Phase I study of 4SC's resminostat indicates efficacy in biliary tract can..
08/31 DGAP-NEWS : 4SC to present at upcoming scientific conferences
08/10 DGAP-NEWS : 4SC provides Q2 and 6M 2017 update
08/03 DGAP-NEWS : 4SC AG: Conference call to be hosted on 10 August 2017 to present th..
08/01 DGAP-NEWS : 4SC AG was granted a fundamental composition of matter patent for 4S..
07/24 DGAP-DD : 4SC AG english
07/18 DGAP-NEWS : 4SC licenses Kv1.3 inhibitors to Maruho
07/13 DGAP-NVR : 4SC AG: Release according to Article 26a of the WpHG with the object..
07/13 DGAP-DD : 4SC AG english
07/11 DGAP-DD : 4SC AG english
More news
Sector news : Biotechnology & Medical Research - NEC
09/20DJSANOFI : Alnylam Report Positive Patisiran Phase III Trial, First-Ever for RNAi ..
09/15 Drug industry on tenterhooks as Maryland price-gouging law nears
09/07 New AstraZeneca, Amgen drug looks strong rival in severe asthma
08/30DJFDA Approves Pioneering Cancer Treatment With $475,000 Price Tag -- Update
08/30DJFDA Approves Pioneering Cancer Treatment With $475,000 Price Tag
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
09/13#ovariancancer Epigenetics Drug Proves Effective in Phase I for Lethal Cancer.. 
09/13Phase I study of 4SC's resminostat indicates efficacy in biliary tract cancer.. 
08/314SC to present at upcoming scientific conferences  
08/104SC provides Q2 and 6M 2017 update  
01/264SC AG Release: Overall Survival Benefit For Resminostat In First-Line Liver .. 
More tweets
Qtime:5
News from SeekingAlpha
2016 4SC AG Presents at The German Equity Forum 2016
Chart 4SC AG
Duration : Period :
4Sc AG Technical Analysis Chart | VSC | DE000A14KL72 | 4-Traders
Technical analysis trends 4SC AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Average target price 3,50 €
Spread / Average Target -34%
EPS Revisions
Managers
NameTitle
Jason Loveridge Chairman-Management Board & CEO
Clemens M. Doppler Chairman-Supervisory Board
Susanne Danhauser-Riedl Chief Medical Officer
Roland Baumgartner Chief Scientific Officer
Manfred Rüdiger Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
4SC AG107.47%193
INCYTE CORPORATION14.56%24 235
QUINTILES IMS HOLDINGS INC24.44%20 267
LONZA GROUP57.01%19 853
CELLTRION, INC.--.--%15 738
ALNYLAM PHARMACEUTICALS, INC.204.06%10 359